EUVIMEDEUVIMED entdecken
Crossref

Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma

Ya-Hsuan Chang, Chih-Hsiang Yu iD, Meng-Yao Lu, Shiann-Tarng Jou, Chien-Yu Lin, Kai-Hsin Lin, Hsiu-Hao Chang iD, Yu-Ling Ni, Shu-Wei Chou iD, Kuan-Yin Ko, Dong-Tsamn Lin, Wen-Ming Hsu und 2 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Ya-Hsuan Chang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular and Genomic Medicine, National Health Research Institute, Miaoli, Taiwan. Hauptthemen laut MEDLINE: Neuroblastoma, Mutation. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan, National Taiwan University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Neuroblastoma is a pediatric malignancy with heterogeneous clinical outcomes. Our aim was to identify prognostic genetic markers for patients with neuroblastoma, who were treated with the Taiwan Pediatric Oncology Group (TPOG) neuroblastoma N2002 protocol, to improve risk stratification and inform treatment.

Methods

Our analysis was based on 53 primary neuroblastoma specimens, diagnosed pre‐chemotherapy, and 11 paired tumor relapse specimens. Deep sequencing of 113 target genes was performed using a custom panel. Multiplex ligation‐dependent probe amplification was performed to identify clinical outcomes related to copy‐number variations.

Results

We identified 128 variations associated with survival, with the number of variations being higher in the relapse than that in the diagnostic specimen ( p = .03). The risk of event and mortality was higher among patients with a tumor mutational burden ≥10 than that in patients with a lower burden ( p < .0001). Multivariate analysis identified tumor mutational burden, MYCN amplification, and chromosome 3p deletion as significant prognostic factors, independent of age at diagnosis, sex, and tumor stage. The 5‐year event‐free survival and overall survival rate was lower among patients with high tumor burden than in patients with low tumor burden. Furthermore, there was no survival of patients with an ALK F1147L variation at 5 years after diagnosis.

Conclusions

Genome sequencing to determine the tumor mutational burden and ALK variations can improve the risk classification of neuroblastoma and inform treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaMutationHumansMaleFemaleChild, PreschoolInfantChildPrognosisBiomarkers, TumorSurvival RateFollow-Up StudiesDNA Copy Number VariationsTumor BurdenAntineoplastic Combined Chemotherapy ProtocolsAdolescent

Stichwörter der Autor:innen

ALK variationsMYCN amplificationsTMBneuroblastomarisk‐directed therapy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Institute of Molecular and Genomic Medicine, National Health Research Institute, Miaoli, Taiwan.
  • Institute of Statistical Science Academia Sinica, Taipei, Taiwan.
  • Departments of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
  • Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Pediatrics, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.

ORCID-Profile: Chih-Hsiang Yu, Hsiu-Hao Chang, Shu-Wei Chou, Yung-Li Yang

Förderung

  • Ministry of Science and Technology, Taiwan
  • National Taiwan University Hospital

Zitieren

APA

Chang, Y. H., Yu, C. H., Lu, M. Y., Jou, S. T., Lin, C. Y., Lin, K. H., Chang, H. H., Ni, Y. L., Chou, S. W., Ko, K. Y., Lin, D. T., Hsu, W. M., Chen, H. Y., & Yang, Y. L. (2024). Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31176

Vancouver

Chang YH, Yu CH, Lu MY, Jou ST, Lin CY, Lin KH, et al. Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31176

BibTeX
@article{Chang2024,
  author = {Chang, Ya-Hsuan and Yu, Chih-Hsiang and Lu, Meng-Yao and Jou, Shiann-Tarng and Lin, Chien-Yu and Lin, Kai-Hsin and Chang, Hsiu-Hao and Ni, Yu-Ling and Chou, Shu-Wei and Ko, Kuan-Yin and Lin, Dong-Tsamn and Hsu, Wen-Ming and Chen, Hsuan-Yu and Yang, Yung-Li},
  title = {Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31176}
}
Kostenlos starten →